Abstract
To assess the safety and efficacy of the B lymphocyte (anti-CD20) antibody, rituximab, in the treatment of steroid-resistant moderately active ulcerative colitis (UC).
| Original language | English |
|---|---|
| Pages (from-to) | 1520-1526 |
| Number of pages | 7 |
| Journal | Gut |
| Volume | 60 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2011 |
Keywords
- Adult
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD19
- Antigens, CD20
- B-Lymphocytes
- Colitis, Ulcerative
- Colon
- Female
- Glucocorticoids
- Humans
- Immunohistochemistry
- Immunosuppressive Agents
- Lymphocyte Count
- Middle Aged
- Remission Induction